Edwards Lifesciences (EW) Rating Reiterated by Stifel Nicolaus

Share on StockTwits

Edwards Lifesciences (NYSE:EW)‘s stock had its “positive” rating reiterated by research analysts at Stifel Nicolaus in a research note issued on Thursday, The Fly reports.

EW has been the subject of a number of other reports. Guggenheim lowered shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating in a research note on Tuesday, October 2nd. Zacks Investment Research raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a research note on Wednesday, September 26th. ValuEngine raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Wednesday, September 19th. SunTrust Banks increased their target price on shares of Edwards Lifesciences to $200.00 and gave the company a “buy” rating in a research note on Friday, September 28th. Finally, Bank of America lowered shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating in a research note on Tuesday, October 2nd. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $162.85.

Shares of NYSE:EW opened at $157.21 on Thursday. The company has a market capitalization of $34.14 billion, a PE ratio of 36.54, a P/E/G ratio of 2.15 and a beta of 0.90. Edwards Lifesciences has a twelve month low of $110.68 and a twelve month high of $175.00. The company has a quick ratio of 1.85, a current ratio of 2.31 and a debt-to-equity ratio of 0.18.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, October 23rd. The medical research company reported $1.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.05. The company had revenue of $906.60 million during the quarter, compared to analyst estimates of $927.56 million. Edwards Lifesciences had a net margin of 20.67% and a return on equity of 30.11%. The business’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.84 EPS. Equities analysts forecast that Edwards Lifesciences will post 4.7 earnings per share for the current year.

In related news, VP Catherine M. Szyman sold 700 shares of the company’s stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $142.64, for a total value of $99,848.00. Following the completion of the sale, the vice president now owns 27,772 shares in the company, valued at approximately $3,961,398.08. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Michael A. Mussallem sold 32,900 shares of the company’s stock in a transaction that occurred on Wednesday, September 12th. The shares were sold at an average price of $144.02, for a total transaction of $4,738,258.00. Following the completion of the sale, the chief executive officer now owns 76,026 shares of the company’s stock, valued at approximately $10,949,264.52. The disclosure for this sale can be found here. In the last 90 days, insiders sold 187,156 shares of company stock valued at $27,603,513. 1.84% of the stock is owned by insiders.

Large investors have recently modified their holdings of the stock. Honkamp Krueger Financial Services Inc. purchased a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at approximately $106,000. SRS Capital Advisors Inc. increased its stake in Edwards Lifesciences by 317.5% in the 3rd quarter. SRS Capital Advisors Inc. now owns 668 shares of the medical research company’s stock valued at $116,000 after buying an additional 508 shares during the period. TLP Group LLC increased its stake in Edwards Lifesciences by 163.6% in the 3rd quarter. TLP Group LLC now owns 680 shares of the medical research company’s stock valued at $118,000 after buying an additional 422 shares during the period. LFA Lugano Financial Advisors SA acquired a new position in Edwards Lifesciences in the 3rd quarter valued at approximately $121,000. Finally, Prime Capital Investment Advisors LLC increased its stake in Edwards Lifesciences by 577.9% in the 3rd quarter. Prime Capital Investment Advisors LLC now owns 705 shares of the medical research company’s stock valued at $123,000 after buying an additional 601 shares during the period. Institutional investors and hedge funds own 82.55% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Recommended Story: Dividend Stocks – Are They Right For You?

The Fly

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.